{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:49:22Z","timestamp":1782103762103,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostatic incidental uptake (PIU) may have clinical relevance, and progress in molecular imaging is likely to increase its detection. This study aimed to provide updated pooled estimates of the prevalence and malignancy risk of PIU identified on [18F]FDG positron emission tomography\/computed tomography (PET\/CT) and on PET\/CT scans using radiotracers other than [18F]FDG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search for studies on PIU was performed in two databases, screening all available literature up to 30 October 2025. Only original articles reporting PIU were included. A proportion meta-analysis was conducted on a patient-based analysis using a random-effects model to calculate pooled prevalence and malignancy rates. In addition, several variables were evaluated as potential predictors of malignant PIU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four studies met the inclusion criteria. PET\/CT was performed with [18F]FDG in 23 studies and with radiolabeled somatostatin analogues (SSA) in one study. The pooled prevalence of PIU was 1.7% for [18F]FDG PET\/CT, whereas the prevalence observed in the single eligible SSA PET\/CT study was 4.5%. The pooled malignancy rates among PIU cases that underwent further evaluation or biopsy were 21.3% and 59.7%, respectively; no malignant lesions were reported in the SSA study. Malignant PIUs showed a higher mean age and a higher mean SUVmax compared with benign PIUs. A peripheral location of PIU emerged as a predictor of malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PIU is detected in approximately 1.7% of [18F]FDG PET\/CT scans in men and is associated with a relevant risk of malignancy. Accordingly, PIU should prompt individualized clinical correlation, particularly when uptake is focal, peripherally located, or associated with elevated PSA or other suspicious prostate-directed findings. More well-designed studies are required to better define the clinical impact of PIU and to determine its prevalence and clinical relevance when using PET tracers other than [18F]FDG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1872033","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:34:18Z","timestamp":1782102858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostatic incidental uptake on PET\/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk"],"prefix":"10.3389","volume":"16","author":[{"given":"Chiara","family":"Martinello","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale","place":["Bellinzona, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare Michele","family":"Iacovitti","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale","place":["Bellinzona, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Marin","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, Central University Emergency Military Hospital \u201cDr. Carol Davila\u201d","place":["Bucharest, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavko","family":"Tasevski","sequence":"additional","affiliation":[{"name":"University Institute for Positron Emission Tomography","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cuzzocrea","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale","place":["Bellinzona, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale","place":["Bellinzona, Switzerland"]},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera, Lugano","place":["Italiana, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, ASST Spedali Civili, University of Brescia","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale","place":["Bellinzona, Switzerland"]},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera, Lugano","place":["Italiana, Switzerland"]},{"name":"Faculty of Biology and Medicine, University of Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2021.03.002","article-title":"General review on the current management of incidental findings on cross-sectional imaging: What guidelines to use, how to follow them, and management and medical-legal considerations","volume":"59","author":"Alabousi","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2387","article-title":"Prevalence and outcomes of incidental imaging findings: umbrella review","volume":"361","author":"O'Sullivan","year":"2018","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06915-3","article-title":"EANM\/SNMMI guideline\/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0","volume":"52","author":"Abikhzer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18502\/fbt.v11i4.16515","article-title":"Advancing oncology through imaging: Evaluating FDG-PET's role in cancer diagnosis and staging","volume":"11","author":"Elhaie","year":"2024","journal-title":"Front BioMed Technol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3413\/nukmed-0668-14-05","article-title":"Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of Malignancy","volume":"53","author":"Bertagna","year":"2014","journal-title":"Nuklearmedizin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-016-0219-2","article-title":"Systematic reviews and meta-analyses of diagnostic studies: A practical guideline","volume":"5","author":"Sadeghi","year":"2017","journal-title":"Clin Transl Imaging"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B9","unstructured":"Study Quality Assessment Tools"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/19887771","article-title":"Significance of incidental focal uptake in prostate on FDG PET\/CT","volume":"83","author":"Han","year":"2010","journal-title":"Br J Radiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-011-0092-x","article-title":"Incidental focal (18)F-FDG uptake in the prostate: Clinical significance and differential diagnostic criteria","volume":"45","author":"Cho","year":"2011","journal-title":"Nucl Med Mol Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-012-0663-7","article-title":"Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images","volume":"27","author":"Hwang","year":"2013","journal-title":"Ann Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/476786","article-title":"What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET\/CT for other Malignancies","volume":"2013","author":"Bhosale","year":"2013","journal-title":"Int J Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3011","article-title":"Incidental prostate \u00b98F-FDG uptake without calcification indicates the possibility of prostate cancer","volume":"31","author":"Seino","year":"2014","journal-title":"Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2014.01.019","article-title":"Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"38","author":"Yang","year":"2014","journal-title":"Clin Imaging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.20.8699","article-title":"Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans","volume":"15","author":"Kang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2015.56.4.288","article-title":"Prevalence and clinical significance of incidental (18)F-fluoro-2-deoxyglucose uptake in prostate","volume":"56","author":"Kwon","year":"2015","journal-title":"Korean J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-015-0453-y","article-title":"Multicentre study of 18F-FDG-PET\/CT prostate incidental uptake","volume":"33","author":"Bertagna","year":"2015","journal-title":"Jpn J Radiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-015-0520-y","article-title":"Does focal incidental 18F-FDG PET\/CT uptake in the prostate have significance","volume":"40","author":"Brown","year":"2015","journal-title":"Abdom Imaging"},{"key":"B20","article-title":"Clinical significance of incidental FDG uptake in the prostate gland detected by PET\/CT","volume":"8","author":"Sahin","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.11.025","article-title":"Clinical relevance of incidental prostatic lesions on FDG-positron emission tomography\/computerized tomography-should patients receive further evaluation","volume":"195","author":"Reesink","year":"2016","journal-title":"J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-015-0364-y","article-title":"Granulomatous prostatitis after intravesical Bacillus Calmette-Gu\u00e9rin instillation therapy: A potential cause of incidental F-18 FDG uptake in the prostate gland on F-18 FDG PET\/CT in patients with bladder cancer","volume":"50","author":"Kim","year":"2016","journal-title":"Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12924","article-title":"Retrospective chart analysis of incidental findings detected by (18) F-fluorodeoxyglucose-PET\/CT in patients with cutaneous Malignant melanoma","volume":"14","author":"Conrad","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/mnm.0000000000000668","article-title":"Clinical significance of incidental prostatic fluorine-18-fluorodeoxyglucose uptake in the diagnosis of infectious prostatitis in adult males","volume":"38","author":"Lee","year":"2017","journal-title":"Nucl Med Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clinimag.2015.03.011","article-title":"Clinical significance of 18F-fluorodeoxyglucose avid prostate gland incidentalomas on positron emission tomography\/computed tomography","volume":"26","author":"Makis","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v9.i9.350","article-title":"Clinical significance of prostate 18F-labelled fluorodeoxyglucose uptake on positron emission tomography\/computed tomography: A five-year review","volume":"9","author":"Chetan","year":"2017","journal-title":"World J Radiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5976","article-title":"Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography","volume":"14","author":"Mannas","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/a-1525-7607","article-title":"Prostate incidentaloma on 18F-fluorodeoxyglucose positron emission tomography: Diagnostic value of volumetric positron emission tomography parameters","volume":"60","author":"\u015eahin","year":"2021","journal-title":"Nuklearmedizin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i34.12532","article-title":"Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon\/rectum, thyroid, and prostate: With a brief literature review","volume":"10","author":"Lee","year":"2022","journal-title":"World J Clin cases"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2023.2280685","article-title":"18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake","volume":"20","author":"Nieri","year":"2023","journal-title":"Expert Rev Med Devices"},{"key":"B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ajur.2023.01.007","article-title":"The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography\/computed tomography for non-prostate cancer-related pathology: A single centre retrospective study","volume":"11","author":"Franklin","year":"2024","journal-title":"Asian J Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12957-024-03578-0","article-title":"Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET\/CT","volume":"22","author":"\u015eam \u00d6zdemir","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912571","article-title":"Clinical significance of atypical 68Ga-DOTATOC prostatic uptake on PET\/CT: A ten-year review","volume":"26","author":"Gossili","year":"2023","journal-title":"Hell J Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170774","article-title":"Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT","volume":"91","author":"Pencharz","year":"2018","journal-title":"Br J Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1607227","article-title":"Diagnostic value of dual-tracer PET\/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review","volume":"12","author":"Iacovitti","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:34:32Z","timestamp":1782102872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1872033"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1872033","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1872033"}}